Inhibition of Lipoprotein-Associated Phospholipase A2 Ameliorates Inflammation and Decreases Atherosclerotic Plaque Formation in ApoE-Deficient Mice
Open Access
- 31 August 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (8) , e23425
Abstract
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is thought to play modulatory roles in the development of atherosclerosis. Here we evaluated the effects of a specific lp-PLA2 inhibitor on atherosclerosis in ApoE-deficient mice and its associated mechanisms. ApoE-deficient mice fed an atherogenic high-fat diet for 17 weeks were divided into two groups. One group was administered the specific lp-PLA2 inhibitor, darapladib (50 mg/kg/day; p.o.) daily for 6 weeks, while the control group was administered saline. We observed no differences in body weight and serum lipids levels between the two groups at the end of the dietary period. Notably, serum lp-PLA2 activity as well as hs-CRP (C-reactive protein) and IL-6 (Interleukin-6) levels were significantly reduced in the darapladib group, compared with the vehicle group, while the serum PAF (platelet-activating factor) levels were similar between the two groups. Furthermore, the plaque area through the arch to the abdominal aorta was reduced in the darapladib group. Another finding of interest was that the macrophage content was decreased while collagen content was increased in atherosclerotic lesions at the aortic sinus in the darapladib group, compared with the vehicle group. Finally, quantitative RT-PCR performed to determine the expression patterns of specific inflammatory genes at atherosclerotic aortas revealed lower expression of MCP-1, VCAM-1 and TNF-α in the darapladib group. Inhibition of lp-PLA2 by darapladib leads to attenuation of in vivo inflammation and decreased plaque formation in ApoE-deficient mice, supporting an anti-atherogenic role during the progression of atherosclerosis.Keywords
This publication has 34 references indexed in Scilit:
- Concept of Vulnerable/Unstable PlaqueArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Τhe role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasmaBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2009
- Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2)Cardiovascular Drugs and Therapy, 2008
- Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque developmentNature Medicine, 2008
- Enhanced Expression of Lp-PLA 2 and Lysophosphatidylcholine in Symptomatic Carotid Atherosclerotic PlaquesStroke, 2008
- Oxidized phospholipids reduce ventilator-induced vascular leak and inflammation in vivoCritical Care, 2008
- Association Between Lipoprotein-Associated Phospholipase A2 and Cardiovascular Disease: A Systematic ReviewMayo Clinic Proceedings, 2007
- Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam StudyEuropean Heart Journal, 2006
- Local Expression of Platelet-Activating Factor-Acetylhydrolase Reduces Accumulation of Oxidized Lipoproteins and Inhibits Inflammation, Shear Stress-Induced Thrombosis, and Neointima Formation in Balloon-Injured Carotid Arteries in Nonhyperlipidemic RabbitsCirculation, 2005
- Activation of ICAM-1 promoter by lysophosphatidylcholine: Possible involvement of protein tyrosine kinasesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1997